Press Releases from Healthcare Opportunity (1 total)
England’s NICE rejects Novartis’ migraine treatment drug Aimovig
The National Institute for Health and Care Excellence (NICE), the public body under the Department of Health in England, has reportedly rejected Novartis’ migraine treatment drug Aimovig (erenumab). As per trusted sources, the regulator stated that the unique migraine prevention treatment is not cost-effective.
According to a report by PharmaPhorum, the draft guidance is a setback for the pharma giant as Aimovig is the first drug among a new class of…
